These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 25294423)
1. Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL. el Aziz LM Med Oncol; 2014 Nov; 31(11):244. PubMed ID: 25294423 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases]. Fan Y; Huang ZY; Luo LH; Yu HF Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458 [TBL] [Abstract][Full Text] [Related]
3. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071 [TBL] [Abstract][Full Text] [Related]
4. Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma. Zhong DT; Shi CM; Chen Q; Huang JZ; Liang JG Ann Hematol; 2012 Nov; 91(11):1757-63. PubMed ID: 22790106 [TBL] [Abstract][Full Text] [Related]
5. The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience. Batgi H; Merdin A; Dal MS; Kızıl Çakar M; Yıldız J; Başçı S; Uncu Ulu B; Yiğenoğlu TN; Darçın T; Şahin D; Bakırtaş M; Tetik A; İskender D; Altuntaş F J Oncol Pharm Pract; 2020 Dec; 26(8):1857-1863. PubMed ID: 32098553 [TBL] [Abstract][Full Text] [Related]
6. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma. Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180 [TBL] [Abstract][Full Text] [Related]
8. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma. Hou Y; Wang HQ; Ba Y Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study. Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732 [TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression. Elsamany S; Farooq MU; Elsirafy M; Shamaa S; Sakr M Med Oncol; 2014 Mar; 31(3):872. PubMed ID: 24496564 [TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331 [TBL] [Abstract][Full Text] [Related]
14. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. Bi J; Espina BM; Tulpule A; Boswell W; Levine AM J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828 [TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience. Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657 [TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Baetz T; Belch A; Couban S; Imrie K; Yau J; Myers R; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R; Crump M Ann Oncol; 2003 Dec; 14(12):1762-7. PubMed ID: 14630682 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. Fosså A; Santoro A; Hiddemann W; Truemper L; Niederle N; Buksmaui S; Bonadonna G; Seeber S; Nowrousian MR J Clin Oncol; 1999 Dec; 17(12):3786-92. PubMed ID: 10577850 [TBL] [Abstract][Full Text] [Related]
18. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma. Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307 [TBL] [Abstract][Full Text] [Related]
19. Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. Jo JC; Baek JH; Lee JH; Joo YD; Bae SH; Lee JL; Lee JH; Kim DY; Lee WS; Ryoo HM; Choi Y; Kim H; Lee KH; Asia Pac J Clin Oncol; 2016 Jun; 12(2):159-66. PubMed ID: 26956432 [TBL] [Abstract][Full Text] [Related]
20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]